Skip to main content

Table 4 Effectiveness of 12-week adalimumab treatment in patients with PsA stratified by prior anti-TNF therapy

From: Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy

Outcome measure No prior ETN/IFX Prior ETN or IFX or both
  (n = 376) (n = 66)
TJC (0 to 78)   
   Baseline 16 15
  10, 27 8, 25
   Change, Baseline to week 12 -10 -10
  -17, -5 -16, -3
SJC (0 to 76)   
   Baseline 9 7
  5, 13 5, 11
   Change, Baseline to week 12 -7 -5
  -10, -3 -8, -3
HAQ DI (0 to 3)   
   Baseline 1.25 1.44
  0.75, 1.63 1.00, 1.75
   Change, Baseline to week 12 -0.50 -0.50
  -0.88, -0.13 -0.75, -0.25
Patients with nail psoriasis (NAPSI ≥ 1) n = 223 n = 36
NAPSI (0 to 80)   
   Baseline 14 18
  5, 30 10, 37
   Change, Baseline to week 12 -6 -6
  -14, -2 -15, -1
  1. Values are expressed as median and quartile 1, quartile 3. ETN, etanercept; HAQ DI, Health Assessment Questionnaire Disability Index; IFX, infliximab; NAPSI, Nail Psoriasis Severity Index (only fingernails); PsA, psoriatic arthritis; SJC, swollen joint count; TJC, tender joint count; TNF, tumor necrosis factor.